Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C, Drings P, von Pawel J, Ricci S, Dornoff W, van Walree N, ten Bokkel Huinink W, Chemaissani A, Stahel P, Bergman B, Wagenius G, Sederholm C, Mattson K, Liippo K, Kellokumpu-Lehtinen P. Manegold C, et al. Among authors: wagenius g. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-13-S8-17. Semin Oncol. 1997. PMID: 9207310 Clinical Trial.
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W. Manegold C, et al. Among authors: wagenius g. Ann Oncol. 1997 Jun;8(6):525-9. doi: 10.1023/a:1008207731111. Ann Oncol. 1997. PMID: 9261520 Free article. Clinical Trial.
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, Walree NV, Manegold C. ten Bokkel Huinink WW, et al. Among authors: wagenius g. Lung Cancer. 1999 Nov;26(2):85-94. doi: 10.1016/s0169-5002(99)00067-7. Lung Cancer. 1999. PMID: 10568679 Clinical Trial.
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. Pirker R, et al. Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9. Lancet. 2009. PMID: 19410716 Clinical Trial.
Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A, Wagenius G, Rylander H, Brodin O, Holmberg E, Lödén B, Ewers SB, Bergström S, Wichardt-Johansson G, Nilsson K, Ekberg L, Sederholm C, Nyman J. Hallqvist A, et al. Among authors: wagenius g. Lung Cancer. 2011 Feb;71(2):166-72. doi: 10.1016/j.lungcan.2010.05.011. Epub 2010 Jun 11. Lung Cancer. 2011. PMID: 20541833 Clinical Trial.
73 results